ProShare Advisors
DNTH icon

ProShare Advisors’s Dianthus Therapeutics DNTH Stock Holding History

ProShare Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$436K Buy
+5,197
New +$301K ﹤0.01% 1146
2022
Q2 		– Sell
-731
Closed -$34K – 1881
2022
Q1 		$34K Sell
731
-195
-21% -$10.7K ﹤0.01% 2143
2021
Q4 		$67K Sell
926
-96
-9% -$9.65K ﹤0.01% 2248
2021
Q3 		$119K Sell
1,022
-117
-10% -$13.6K ﹤0.01% 1891
2021
Q2 		$178K Buy
1,139
+376
+49% +$69.1K ﹤0.01% 2176
2021
Q1 		$145K Buy
763
+10
+1% +$1.68K ﹤0.01% 2114
2020
Q4 		$94K Buy
753
+109
+17% +$12.4K ﹤0.01% 1997
2020
Q3 		$70K Buy
+644
New +$76.3K ﹤0.01% 1563
2020
Q1 		– Sell
-690
Closed -$167K – 1280
2019
Q4 		$167K Sell
690
-103
-13% -$19.2K ﹤0.01% 1630
2019
Q3 		$130K Sell
793
-5
-0.6% -$950 ﹤0.01% 1514
2019
Q2 		$188K Sell
798
-4
-0.5% -$989 ﹤0.01% 1452
2019
Q1 		$211K Buy
802
+74
+10% +$12.8K ﹤0.01% 1444
2018
Q4 		$66K Buy
+728
New +$99.2K ﹤0.01% 1513

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ProShare Advisors's DNTH Position: Q1 2026 in Review

ProShare Advisors opened a new position in Dianthus Therapeutics (DNTH) in Q1 2026: 5,197 shares worth $436K. The stake represents ﹤0.01% of the portfolio and ranks #1146 among its holdings. This is a return to the name: ProShare Advisors previously reported a position in DNTH as recently as Q1 2022.

ProShare Advisors first reported a position in DNTH in Q4 2018 and has held it in 13 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • ProShare Advisors held 5,197 shares of Dianthus Therapeutics worth $436K as of Q1 2026.
  • Dianthus Therapeutics was a new ProShare Advisors position in Q1 2026.
  • Dianthus Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1146 holding.
  • ProShare Advisors first reported a position in Dianthus Therapeutics in Q4 2018 and has held it in 13 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.